Skip to main content
J

JILIN JIAN YISHENG PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 002566 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,259 across all filing types
Latest filing 2026-04-16 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002566

About JILIN JIAN YISHENG PHARMACEUTICAL CO.,LTD.

https://www.yisheng-pharm.com

Jilin Jian Yisheng Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products, health supplements, and cosmetics. The company focuses on integrating traditional Chinese medicine with modern pharmacological techniques. Its core product portfolio includes treatments for cardiovascular diseases, cerebrovascular conditions, and various health-strengthening supplements. A significant portion of its operations involves the deep processing of natural resources such as ginseng and deer antler, leveraging specialized extraction technologies to produce standardized extracts and finished dosage forms like capsules, tablets, and oral liquids. The firm maintains an integrated industrial chain encompassing raw material cultivation, scientific research, and large-scale production facilities. Its products are primarily marketed to healthcare providers and retail pharmacies, emphasizing quality control and the therapeutic efficacy of natural ingredients.

Recent filings

Filing Released Lang Actions
关于公司对会计师事务所2025年度履职情况的评估报告
Audit Report / Information Classification · 1% confidence The document is a formal evaluation report by the company on the external auditor’s 2025 performance, detailing the auditor’s qualifications, audit procedures, and the company’s assessment of their work. It is audit‐related information but not a full annual report or management commentary and goes beyond mere publication notice. This fits the standalone audit report/information category (AR).
2026-04-16 Chinese
2025年年度审计报告
Audit Report / Information Classification · 1% confidence The document is titled “审计报告” and contains an auditor’s opinion, audit scope, key audit matters, and detailed financial statements (balance sheet, income statement, cash flow, equity changes) prepared and signed by a certified public accounting firm. It is a standalone audit report and not an annual report or other notice. Therefore, it matches the Audit Report / Information category.
2026-04-16 Chinese
关于使用闲置自有资金购买理财产品的公告
Regulatory Filings Classification · 1% confidence The document is a corporate announcement by the board on using idle internal funds to purchase wealth‐management products. It does not present financial results or an investor presentation, nor is it a proxy or remuneration statement. It is not raising new capital or issuing shares, so it doesn’t fit CAP, SHA, or POS. As it’s a general regulatory disclosure of a corporate decision/transaction that doesn’t neatly match any specialized category, it falls into the fallback “Regulatory Filings” (RNS).
2026-04-16 Chinese
关于使用闲置自有资金购买理财产品到期赎回的公告
Regulatory Filings
2026-04-10 Chinese
关于使用闲置自有资金购买理财产品到期赎回的公告
Regulatory Filings
2026-04-08 Chinese
关于使用闲置自有资金购买理财产品到期赎回的公告
Regulatory Filings
2026-03-25 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.